Diabetes mellitus in the transplanted kidney

Frontiers in Endocrinology

Volumn 5, Issue AUG, 2014, Pages

  Peev, Vasil ^a   Reiser, Jochen ^a   Alachkar, Nada ^b  

^a RUSH MEDICAL COLLEGE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B17 receptor; Diabetes mellitus; Diabetic nephropathy; Kidney transplant; MTORC1 signaling; New onset of diabetes after transplant; Podocyte; SuPAR

Indexed keywords

ADIPONECTIN; CALCINEURIN INHIBITOR; CASPASE 3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOSPORIN; GLUCOCORTICOID; GLUCOSE TRANSPORTER 2; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN DERIVATIVE; PHOSPHOLIPASE C; TACROLIMUS; TUMOR NECROSIS FACTOR;

ALLOGRAFT; APOPTOSIS; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOWN REGULATION; END STAGE RENAL DISEASE; GENETIC POLYMORPHISM; HUMAN; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

EID: 84987837807     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00141     Document Type: Review

References (55)

1. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol (1998) 9(11):2135-41.
2. Ojo AO, Port FK, Wolfe RA, Mauger EA, Williams L, Berling DP. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis (1994) 24(1):59-64. doi: 10.1016/S0272-6386(12)80160-0
3. Meier-Kriesche HU, Ojo AO, Port FK, Arndorfer JA, Cibrik DM, Kaplan B. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol (2001) 12(6):1293-6.
4. Gaston RS, Basadonna G, Cosio FG, Davis CL, Kasiske BL, Larsen J, et al. Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. Am J Kidney Dis (2004) 44(3):529-42. doi:10.1053/j.ajkd.2004.05.030
5. Gunnarsson R, Arner P, Lundgren G, Magnusson G, Ostman J, Groth CG. Diabetes mellitus-a more-common-than-believed complication of renal transplantation. Transplant Proc (1979) 11(2):1280-1.
6. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant (2003) 3(2):178-85. doi:10.1034/j.1600-6143.2003.00010.x
7. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int (2001) 59(2):732-7. doi:10.1046/j.1523-1755.2001.059002732.x
8. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 75(10 Suppl):SS3-24.
9. Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation (2001) 72(6):1066-72. doi:10.1097/00007890-200109270-00015
10. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol (1998) 26(1):30-3. doi:10.1097/00004836-199801000-00009
11. Ye X, Kuo H-T, Sampaio MS, Jiang Y, Bunnapradist S. Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. Clin Transplant (2011) 25(6):885-91. doi:10.1111/j.1399-0012.2010.01383.x
12. Rodrigo E, Fernández-Fresnedo G, Valero R, Ruiz JC, Piñera C, Palomar R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol (2006) 17(12 Suppl 3):S291-5. doi:10.1681/ASN.2006080929
13. Kaposztas Z, Gyurus E, Kahan BD. New-onset diabetes after renal transplantation: diagnosis, incidence, risk factors, impact on outcomes, and novel implications. Transplant Proc (2011) 43(5):1375-94. doi:10.1016/j.transproceed.2011.04.008
14. Juan Khong M, Ping Chong C. Prevention and management of new-onset diabetes mellitus in kidney transplantation. Neth J Med (2014) 72(3):127-34.
15. Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int (2005) 67(6):2415-21. doi:10.1111/j.1523-1755.2005.00349.x
16. Gourishankar S, Jhangri GS, Tonelli M, Wales LH, Cockfield SM. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant (2004) 4(11):1876-82. doi:10.1111/j.1600-6143.2004.00591.x
17. Numakura K, Satoh S, Tsuchiya N, Horikawa Y, Inoue T, Kakinuma H, et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation (2005) 80(10):1419-24. doi:10.1097/01.tp.0000181142.82649.e3
18. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest (2005) 115(5):1111-9. doi:10.1172/JCI25102
19. Bayés B, Granada ML, Pastor MC, Lauzurica R, Salinas I, Sanmartí A, et al. Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant (2007) 7(2):416-22.
20. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 286(3):327-34. doi:10.1001/jama.286.3.327
21. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet (2003) 361(9353):226-8. doi:10.1016/S0140-6736(03)12255-6
22. Bayés B, Lauzurica R, Granada ML, Serra A, Bonet J, Fontseré N, et al. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation (2004) 78(1):26-30. doi:10.1097/01.TP.0000132561.48217.B1
23. Wang Q, Chen J, Wang Y, Han X, Chen X. Hepatitis C virus induced a novel apoptosis-like death of pancreatic beta cells through a caspase 3-dependent pathway. PLoS One (2012) 7(6):e38522. doi:10.1371/journal.pone.0038522
24. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab (2006) 32(5 Pt 2):539-46. doi:10.1016/S1262-3636(06)72809-9
25. Van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest (2009) 39(2):81-93. doi:10.1111/j.1365-2362.2008.02067.x
26. Dong M, Parsaik AK, Eberhardt NL, Basu A, Cosio FG, Kudva YC. Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation. Diabet Med (2012) 29(7):e1-12. doi:10.1111/j.1464-5491.2012.03617.x
27. Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, Lupescu A, et al. Serum-and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes (2005) 54(4):1090-9. doi:10.2337/diabetes.54.4.1090
28. Zawalich WS, Tesz GJ, Yamazaki H, Zawalich KC, Philbrick W. Dexamethasone suppresses phospholipase C activation and insulin secretion from isolated rat islets. Metabolism (2006) 55(1):35-42. doi:10.1016/j.metabol.2005.06.023
29. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg (2008) 248(4):564-77. doi:10.1097/SLA.0b013e318187d1da
30. Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation (2011) 91(3):334-41. doi:10.1097/TP.0b013e318203c25f
31. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant (2007) 7(6):1506-14. doi:10.1111/j.1600-6143.2007.01749.x
32. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant (2004) 4(4):583-95. doi:10.1046/j.1600-6143.2003.00372.x
33. Øzbay LA, Smidt K, Mortensen DM, Carstens J, Jørgensen KA, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol (2011) 162(1):136-46. doi:10.1111/j.1476-5381.2010.01018.x
34. Plaumann S, Blume R, Börchers S, Steinfelder HJ, Knepel W, Oetjen E. Activation of the dual-leucine-zipper-bearing kinase and induction of beta-cell apoptosis by the immunosuppressive drug cyclosporin A. Mol Pharmacol (2008) 73(3):652-9. doi:10.1124/mol.107.040782
35. Düfer M, Krippeit-Drews P, Lembert N, Idahl LA, Drews G. Diabetogenic effect of cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells. Mol Pharmacol (2001) 60(4):873-9.
36. Isakova T, Xie H, Messinger S, Cortazar F, Scialla JJ, Guerra G, et al. Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation. Am J Transplant (2013) 13(1):100-10. doi:10.1111/j.1600-6143.2012.04281.x
37. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol (2008) 19(7):1411-8. doi:10.1681/ASN.2007111202
38. Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: what does the current evidence tell us? Transplant Proc (2009) 41(6 Suppl):S31-8. doi:10.1016/j.transproceed.2009.06.159
39. Radu RG, Fujimoto S, Mukai E, Takehiro M, Shimono D, Nabe K, et al. Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity. Am J Physiol Endocrinol Metab (2005) 288(2):E365-71. doi:10.1152/ajpendo.00390.2004
40. Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab (2001) 3(6):393-402. doi:10.1046/j.1463-1326.2001.00150.x
41. Shimodahira M, Fujimoto S, Mukai E, Nakamura Y, Nishi Y, Sasaki M, et al. Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism. J Endocrinol (2010) 204(1):37-46. doi:10.1677/JOE-09-0216
42. Balcazar N, Sathyamurthy A, Elghazi L, Gould A, Weiss A, Shiojima I, et al. mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability. J Biol Chem (2009) 284(12):7832-42. doi:10.1074/jbc.M807458200
43. Bhalla V, Nast CC, Stollenwerk N, Tran S, Barba L, Kamil ES, et al. Recurrent and de novo diabetic nephropathy in renal allografts. Transplantation (2003) 75(1):66-71. doi:10.1097/00007890-200301150-00012
44. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol (2007) 27(2):195-207. doi:10.1016/j.semnephrol.2007.01.012
45. Estacio RO, Schrier RW. Diabetic nephropathy: pathogenesis, diagnosis, and prevention of progression. Adv Intern Med (2001) 46:359-408.
46. Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, et al. Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol (2014) 25(7):1415-29. doi:10.1681/ASN.2013050518
47. Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R, et al. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun (2009) 384(4):471-5. doi:10.1016/j.bbrc.2009.04.136
48. Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest (2011) 121(6):2197-209. doi:10.1172/JCI44774
49. Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol (2014). doi:10.1681/ASN.2013111213
50. Theilade S, Lyngbaek S, Hansen TW, Eugen-Olsen J, Fenger M, Rossing P, et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J Intern Med (2014). doi:10.1111/joim.12269
51. Schiel R, Heinrich S, Steiner T, Ott U, Stein G. Long-term prognosis of patients after kidney transplantation: a comparison of those with or without diabetes mellitus. Nephrol Dial Transplant (2005) 20(3):611-7. doi:10.1093/ndt/gfh657
52. Fernández-Fresnedo G, Escallada R, de Francisco ALM, Rodrigo E, Zubimendi JA, Ruiz JC, et al. Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc (2003) 35(2):700. doi:10.1016/S0041-1345(03)00605-5
53. Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int (2006) 69(3):588-95. doi:10.1038/sj.ki.5000116
54. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation (2006) 82(5):603-11. doi:10.1097/01.tp.0000235527.81917.fe
55. Burroughs TE, Swindle J, Takemoto S, Lentine KL, Machnicki G, Irish WD, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation (2007) 83(8):1027-34. doi:10.1097/01.tp.0000259617.21741.95